Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Medical Oncology|February 7, 2025
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancerHeather L McArthur, Sara M Tolaney, Rebecca Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2013
Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapyAli Sadeghi-Naini, Naum Papanicolau, Omar Falou, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Clinical Pharmacokinetics|April 22, 2016
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer PatientsNatalia Sutiman, Joanne Siok Liu Lim, Thomas E Muerdter, et al.
The Lancet. Oncology|August 13, 2017
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung-Bae Kim, Rebecca Dent, Seock-Ah Im, et al.
Histopathology|February 23, 2026
Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA studyCorrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso-Sousa, et al.
Breast (Edinburgh, Scotland)|February 11, 2026
Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study resultsLazar Popovic, Romualdo Barroso-Sousa, Nagi S El Saghir, et al.
International Journal of Cancer|May 29, 2015
Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort studyNirmala Bhoo-Pathy, Helena M Verkooijen, Fuh-Yong Wong, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Psycho-Oncology|January 10, 2018
Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivorsTerence Ng, Sreemanee Raaj Dorajoo, Yin Ting Cheung, et al.
Pageof 8